BioCentury This Week

BioCentury Podcasts
BioCentury Podcasts
  • 5,0 (1)
  • Ciências da Vida
  • Semanalmente

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. -1 dia

    Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

    After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury’s analysts to discuss the company’s recent report on life sciences talent trends, and how those trends are driving property demand. This episode of the BioCentury This Week podcast has been brought to you by CBRE. View full story: https://www.biocentury.com/article/660118 #LifeSciences #BiotechJobs #Workforce #LifeSciencesRealEstate #Talent 00:01 - Sponsor Message: CBRE 00:45 - Industry Inflection Point 04:17 - Report Methodology 10:08 - Growth Beyond Big Hubs 15:28 - Capital Markets Signals 18:48 - AI and Space Use 20:50 - Emerging Talent 26:34 - Up-and-Coming Cities To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson

  2. -3 dias

    Ep. 376 - M&A momentum: 3Q public markets preview

    M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can carry biotech through year-end and what happens if the AI trade goes bust? Editor in Chief Simone Fishburn gives her perspective on what incoming Prime Minister Andy Burnham’s agenda means for U.K. life sciences. The analysts also discuss Ionis’ ATTR-CM miss and Takeda’s orexin program. This episode of the BioCentury This Week podcast has been brought to you by CBRE. View full story: https://www.biocentury.com/article/660118 #BiotechMA #BiotechInvesting #PublicMarkets #LifeSciences #DrugDevelopment 00:01 - Sponsor Message: CBRE 01:46 - 3Q Market Preview 10:54 - Burnham’s Britain 19:40 - Ionis' ATTR-CM Miss 29:12 - Takeda Orexin Program To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 376 - M&A momentum: 3Q public markets preview

  3. 7/07

    Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

    Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit. The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson’s atlases reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress’ probe of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE. View full story: https://www.biocentury.com/article/660033 #ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech 00:01 - Sponsor Message: CBRE 01:15 - Novartis Buying Myricx 08:01 - U.K. Regulation 14:44 - DeGette & FDA Reform 21:51 - Parkinson's Atlas Insights 29:39 - China Trials Probe To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech

  4. 29/06

    Ep. 374 - Parkinson's deep dive & FDA trial reforms

    New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts review the most promising targets and trends shaping the Parkinson’s treatment landscape. The team then turns to AstraZeneca’s build-out of its obesity portfolio, followed by FDA’s Operation TrialBlazer and what the reforms mean for reducing the time to launch a clinical trial in the U.S. — and whether they can help close the gap with China. Finally, the analysts review recent FDA reversals of controversial regulatory decisions made under former Commissioner Marty Makary’s leadership and whether companies and investors can expect this reversion to the mean to carry forward. View full story: https://www.biocentury.com/article/659958 #ParkinsonsDisease #ObesityDrugDevelopment #FDA #ClinicalTrials #DrugDevelopment 00:00 - Introduction 01:40 - Parkinson's New Targets 11:43 - AstraZeneca's Obesity Pipeline 18:37 - FDA's Operation TrialBlazer 27:33 - FDA Leadership Outlook To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 374 - Parkinson's deep dive & FDA trial reforms

  5. 23/06

    Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

    AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeout and the assets AbbVie gains. The analysts then discuss moves by FDA to reverse controversial setbacks that occurred under the agency’s former leadership and assess Acting CDER Director Michael Davis’ memo outlining how his predecessor repeatedly overruled career staff to quash a drug approval. The analysts also discuss continuing signs of political involvement at FDA. Finally, they discuss China NMPA’s first-ever approval of a CAR T for solid tumors, satricabtagene autoleucel (satri-cel) from Carsgen. View full story: https://www.biocentury.com/article/659864 #BiotechMA #Immunology #FDA #CART #ChinaBiotech 00:59 - AbbVie Buys Apogee 05:20 - uniQure U-turn 09:02 - FDA Reversals 12:32 - Tzield Memo 20:53 - Solid Tumor CAR T Approval To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first

  6. 16/06

    Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

    Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $770 million debut by  Parabilis, the largest IPO in the sector’s history. The analysts also discuss the Biosecure Act and U.S. policy toward China; the cachexia pipeline; and BioCentury’s updated Innovation Distillery. View full story: https://www.biocentury.com/article/659773 #BiotechIPO #NASDAQ #BiosecureAct #Cachexia #ChinaBiotech  00:36 - Innovation Distillery 03:56 - Biotech IPOs 10:13 - Biosecure Act, WuXi AppTec 16:03 - Cachexia Pipeline 22:03 - Ouster for RFK Jr.? To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline

  7. 11/06

    Ep. 371 - Moving faster at the academia-industry interface

    Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Rounds-U.S. conference brought together academic innovators, biopharma leaders and early-stage investors to debate key bottlenecks in translation and how to make early-stage R&D investible. Sam Blackman, entrepreneur in residence at GV and co-founder of Day One Biopharmaceuticals, and Aaron Coe, managing director of innovation for the Allen Institute, joined BioCentury’s analysts on stage last week in Seattle for a podcast recording to wrap up Grand Rounds and discuss key takeaways from the event. Editor’s note: We invite you to join BioCentury and Regional Host Chairs Forbion and BGV at our next edition of BioCentury Grand Rounds, scheduled for Sept. 23-25 in Amsterdam. View full story: https://www.biocentury.com/article/659729 #TranslationalScience #DrugDevelopment #BiopharmaInnovation #AcademicInnovation #GrandRoundsUS 00:53 - World-Class Regional Hosts 02:56 - Building Grand Rounds Community 05:21 - Two Nobels, One City 07:43 - AI Goes End-to-End 09:47 - The Data Problem 14:12 - AI, Animals, Australia 19:53 - Study Startup Bottlenecks 26:11 - Early Science Investability To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 371 - Moving faster at the academia-industry interface

  8. 9/06

    Ep. 370 - Calmer waters for FDA; Servier, Lilly deals

    FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses how FDA’s new, interim leaders have changed the tone at the agency and why they are putting medicines derailed under former FDA Commissioner Marty Makary back on track. Usdin also highlights FDA’s new real-time clinical trials initiative. BioCentury’s analysts then turn to deals, including an analysis of the 20 deals Eli Lilly has done this year; Servier’s move to expand in neurology via BD; and Monday’s billion-dollar deals by Incyte, which will acquire Vega Therapeutics, and Johnson & Johnson, which is buying Firefly Bio. The team also discusses Grand Rounds U.S., held last week in Seattle, including the conference’s Rising Star prize winner Sylvain Simon of Fred Hutchinson Cancer Center. View full story: https://www.biocentury.com/article/659699 #FDA #BiopharmaDeals #ClinicalTrials #BiotechMA #GrandRoundsUS 01:23 - Grand Rounds Seattle Takeaways 04:43 - FDA's New Leaders 11:48 - FDA's Real Time Trials Pilot 20:40 - Servier Bets on Neuro 25:33 - Lilly's Deal Spree 30:21 - Dealmaking Roundup To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

    Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Ver tudo (387)

Classificações e críticas

Sobre

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Informação

  • Canal
    BioCentury Podcasts
  • Autoria
    BioCentury
  • Anos em atividade
    2020 - 2026
  • Episódios
    387
  • Classificação
    Para todos
  • Copyright
    © 2026 BioCentury Inc. All Rights Reserved.
  • Site do programa
    BioCentury This Week

Mais de BioCentury Podcasts

Talvez também goste